生物制药企业Azitra Inc近日宣布,其已正式新增MD安德森癌症中心作为关键临床研究基地,将共同推进候选药物Atr-04的一期/二期人体试验。该试验主要聚焦于评估Atr-04在治疗表皮生长因子受体抑制剂引发的相关皮肤皮疹方面的安全性与初步疗效。
生物制药企业Azitra Inc近日宣布,其已正式新增MD安德森癌症中心作为关键临床研究基地,将共同推进候选药物Atr-04的一期/二期人体试验。该试验主要聚焦于评估Atr-04在治疗表皮生长因子受体抑制剂引发的相关皮肤皮疹方面的安全性与初步疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.